Q-linea Q4 2023 update: Increasing commercial interest with a slow sales conversion - Redeye

Q-linea is making progress, including successful tenders, commercial evaluations, study support and partner discussions for the US market. The actual reported Q4 sales reflects the slow sales conversion process and the OPEX is high ahead of the next round of savings. The Italian market continues to be the most active market followed by France and Germany. Q-linea is also at the final stage of an FDA approval.

Länk till analysen i sin helhet: https://www.redeye.se/research/988181/q-linea-q4-2023-update-increasing-commercial-interest-with-a-slow-sales-conversion?utm_source=finwire&utm_medium=RSS